ScreenerHero

DNLI Denali Therapeutics Inc.

NAS · US · Healthcare · Biotechnology · denalitherapeutics.com
19.16USD-0.62%Mkt Cap: 3.06B $P/E: —

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap3.06B USD
Enterprise Value2.41B USD
Revenue (TTM)3.60M USD
Gross Profit-397.21M USD
Net Income (TTM)-512.54M USD
Revenue/Share0.02 USD
Last Price19.16 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees503
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-7.97
PEG—
EV/EBITDA-4.58
EV/Revenue668.44
P/S855.12
P/B3.69
EPS (TTM)-2.75
EPS (Forward)-2.42
52W Range
13.1443% of range27.30
52W High27.30 USD
52W Low13.14 USD
Profitability
Gross Margin0.00%
Oper. Margin-3601.30%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-50.56%
ROA-44.77%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-412.60M USD
CapEx (TTM)9.50M USD
FCF Margin-7450.83%
FCF Yield-8.77%
Net Debt-672.78M USD
Net Debt/EBITDA1.28
Balance Sheet
Debt/Equity0.04
Current Ratio8.37
Quick Ratio7.95
Book Value/Sh5.23 USD
Cash/Share4.45 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)36.06 USD
Upside (mean)+88.2%
Target Range27.00 USD – 42.00 USD
27.00+88.2% to mean42.00
# Analysts16
Ownership
Shares Out.159.85M
Float155.10M
Insiders4.61%
Institutions101.29%
Short Interest
Short Ratio14.3d
Short % Float11.31%
Short % Out.10.72%
Shares Short17.14M
Short (prev mo.)17.96M
Technical
SMA 5022.80 (-16.0%)
SMA 20021.07 (-9.1%)
Beta1.02
S&P 52W Chg16.45%
Avg Vol (30d)1.64M
Avg Vol (10d)1.93M
Technical Indicators
RSI (14)31.3
MACD-0.8915
MACD Signal-0.8354
MACD Hist.-0.0561
BB Upper22.14 USD
BB Middle20.61 USD
BB Lower19.08 USD
BB Width14.88%
ATR (14)0.8435 USD
Vol Ratio (20d)0.70x